Grants and Contributions:
Title:
Validation of a unique high precision Cold Plasma Device for breast cancer treatment – Phase 3
Agreement Number:
975628
Agreement Value:
$202,810.00
Agreement Date:
Jun 1, 2021 - Mar 31, 2023
Description:
This project will allow to prepare a unique high precision cold plasma device prototype for breast cancer treatment so it can be authorized by Health Canada for an investigational testing (first-in-human) clinical trial.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H4A 2T7
Reference Number:
172-2021-2022-Q2-975628
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
819165614
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days. The total amended value is 27,760 dollars.
Amendment Date
Dec 5, 2022
Recipient's Legal Name:
NexPlasmaGen Incorporée
Federal Riding Name:
Notre-Dame-de-Grâce--Westmount
Federal Riding Number:
24053
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
339110
Amendments: